^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecelra (afamitresgene autoleucel)

    i
    Company:
    Adaptimmune
    Drug class:
    TCR modulator, MAGE-A4 inhibitor
    Related drugs:
    Apply
    SPEARHEAD-3 Pediatric Study (NCT05642455)
    Phase 1/2
    Adaptimmune
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    09/01/2023
    Primary completion :
    10/01/2026
    Completion :
    07/30/2038
    HLA-A • MAGEA4
    |
    HLA-A*02 • HLA-A2 positive • MAGEA4 expression
    |
    Tecelra (afamitresgene autoleucel)
    Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD-1) (NCT04044768)
    Phase 2
    Adaptimmune
    Recruiting
    Last update posted :
    02/19/2024
    Initiation :
    08/13/2019
    Primary completion :
    10/10/2021
    Completion :
    04/01/2038
    HLA-A • MAGEA4
    |
    HLA-A*02 • MAGEA4 expression
    |
    Tecelra (afamitresgene autoleucel)
    ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) (NCT04044859)
    Phase 1
    Adaptimmune
    Recruiting
    Last update posted :
    02/16/2024
    Initiation :
    08/20/2019
    Primary completion :
    12/23/2025
    Completion :
    04/30/2037
    HLA-A • MAGEA4
    |
    HLA-A*02 • MAGEA4 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecelra (afamitresgene autoleucel) • uzatresgene autoleucel (ADP-A2M4CD8)
    MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922)
    Phase 1
    Adaptimmune
    Active, not recruiting
    Last update posted :
    01/22/2024
    Initiation :
    05/15/2017
    Primary completion :
    12/27/2022
    Completion :
    09/01/2032
    HLA-A • MAGEA4
    |
    HLA-A*02 • HLA-A2 positive
    |
    Tecelra (afamitresgene autoleucel)
    SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer ( SPEARHEAD-2) (NCT04408898)
    Phase 2
    Adaptimmune
    Withdrawn
    Last update posted :
    11/16/2021
    Initiation :
    07/02/2020
    Primary completion :
    12/01/2021
    Completion :
    12/01/2021
    HLA-A • MAGEA4
    |
    HLA-A*02 • HLA-A2 positive • MAGEA4 expression
    |
    Keytruda (pembrolizumab) • Tecelra (afamitresgene autoleucel)